The Evolving Management of Desmoid Fibromatosis.

Desmoid fibromatosis is a rare disease caused by genetic alterations that activate β-catenin. The tumors were previously treated with aggressive surgeries but do not metastasize and may regress spontaneously. For these reasons, in the absence of symptoms and when growth would not induce significant complications, active observation is considered first-line therapy. When intervention is required, surgery can be considered based on anatomy and risk of postoperative recurrence, but increasingly nonoperative therapies such as liposomal doxorubicin or sorafenib are prescribed. Cryoablation, chemoembolization, and high-intensity focused ultrasound can also be used to obtain local control in selected patients. Copyright © 2022 Elsevier Inc. All rights reserved.

Citation

Katherine Prendergast, Sara Kryeziu, Aimee M Crago. The Evolving Management of Desmoid Fibromatosis. The Surgical clinics of North America. 2022 Aug;102(4):667-677

Mesh Tags

PMID: 35952695

search → result